BR112018068342A2 - vacina de vírus zika vivo atenuado - Google Patents
vacina de vírus zika vivo atenuadoInfo
- Publication number
- BR112018068342A2 BR112018068342A2 BR112018068342A BR112018068342A BR112018068342A2 BR 112018068342 A2 BR112018068342 A2 BR 112018068342A2 BR 112018068342 A BR112018068342 A BR 112018068342A BR 112018068342 A BR112018068342 A BR 112018068342A BR 112018068342 A2 BR112018068342 A2 BR 112018068342A2
- Authority
- BR
- Brazil
- Prior art keywords
- attenuated
- virus
- zikv
- vaccines
- zika
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title abstract 9
- 229940124743 Zika virus vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 6
- 229960005486 vaccine Drugs 0.000 abstract 6
- 208000001490 Dengue Diseases 0.000 abstract 4
- 206010012310 Dengue fever Diseases 0.000 abstract 4
- 241000710831 Flavivirus Species 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- 241000907316 Zika virus Species 0.000 abstract 4
- 208000025729 dengue disease Diseases 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 208000020329 Zika virus infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 108091023045 Untranslated Region Proteins 0.000 abstract 1
- 208000001455 Zika Virus Infection Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307170P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021989 WO2017156511A1 (en) | 2016-03-11 | 2017-03-11 | Live attenuated zika virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068342A2 true BR112018068342A2 (pt) | 2019-01-15 |
Family
ID=58428363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068342A BR112018068342A2 (pt) | 2016-03-11 | 2017-03-11 | vacina de vírus zika vivo atenuado |
Country Status (11)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| WO2018129160A1 (en) | 2017-01-06 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live attenuated flavivirus vaccines and methods of using and making same |
| WO2018152158A1 (en) * | 2017-02-14 | 2018-08-23 | Shi Pei Yong | Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| GB201716307D0 (en) * | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Chimeric yellow fever zika virus strain |
| EP3710046A4 (en) | 2017-11-10 | 2021-11-17 | The Research Institute at Nationwide Children's Hospital | RECOMBINANT VECTORS CODING FOR PROTEIN SUBUNITIES OF THE ZIKA VIRUS |
| WO2020051080A1 (en) * | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Dna plasmid-launched live-attenuated vaccines for plus-sense single stranded rna viruses |
| MX2022000038A (es) * | 2019-06-25 | 2022-02-24 | Codagenix Inc | Virus del dengue atenuados. |
| EP4277641A4 (en) * | 2021-02-26 | 2025-03-19 | Duke University | Compositions for and methods of improving gene therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001059093A2 (en) | 2000-02-10 | 2001-08-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FULL-LENGTH INFECTIOUS cDNA CLONES OF TICK BORNE FLAVIVIRUS |
| CA2755964C (en) * | 2001-05-22 | 2017-06-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| CA2472468C (en) | 2002-01-10 | 2015-11-24 | Alexander G. Pletnev | Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| ES2355719T3 (es) | 2002-05-03 | 2011-03-30 | The United States Government As Represented By The Department Of Health And Human Services | Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2. |
| US7622113B2 (en) | 2003-12-08 | 2009-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
| US7851194B2 (en) | 2004-06-14 | 2010-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines |
| DK2054428T3 (da) * | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| US20100316670A1 (en) | 2007-06-14 | 2010-12-16 | Blaney Joseph E | Chimeric sle/dengue type 4 antigenic viruses |
| US20120294889A1 (en) * | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
-
2017
- 2017-03-11 BR BR112018068342A patent/BR112018068342A2/pt not_active IP Right Cessation
- 2017-03-11 JP JP2018547931A patent/JP2019511221A/ja not_active Withdrawn
- 2017-03-11 US US16/083,652 patent/US20190194260A1/en not_active Abandoned
- 2017-03-11 EP EP17714066.2A patent/EP3426292A1/en not_active Withdrawn
- 2017-03-11 WO PCT/US2017/021989 patent/WO2017156511A1/en not_active Ceased
- 2017-03-11 MX MX2018010958A patent/MX2018010958A/es unknown
- 2017-03-11 CN CN201780028836.4A patent/CN109152828A/zh active Pending
- 2017-03-11 KR KR1020187029244A patent/KR20180127397A/ko not_active Withdrawn
- 2017-03-11 CA CA3016697A patent/CA3016697A1/en not_active Abandoned
- 2017-03-11 AU AU2017230112A patent/AU2017230112A1/en not_active Abandoned
-
2018
- 2018-10-10 CO CONC2018/0010874A patent/CO2018010874A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018010958A (es) | 2019-02-07 |
| AU2017230112A1 (en) | 2018-10-04 |
| JP2019511221A (ja) | 2019-04-25 |
| CA3016697A1 (en) | 2017-09-14 |
| KR20180127397A (ko) | 2018-11-28 |
| WO2017156511A8 (en) | 2018-09-27 |
| CO2018010874A2 (es) | 2018-10-22 |
| WO2017156511A1 (en) | 2017-09-14 |
| US20190194260A1 (en) | 2019-06-27 |
| EP3426292A1 (en) | 2019-01-16 |
| CN109152828A (zh) | 2019-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
| BR112014024612A2 (pt) | ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue | |
| EP4218807A3 (en) | Zika virus vaccine | |
| CO2017011245A2 (es) | Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos | |
| BR112017001310A2 (pt) | coronavírus | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| BR112018013168A2 (pt) | vírus mutantes, método de preparação e uso dos mesmos | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| BR112017015789A2 (pt) | vacina de vírus da influenza suína bivalente | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| CL2018001159A1 (es) | Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016) | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| BR112018076234A2 (pt) | vacina contra o vírus da bronquite infecciosa | |
| BR112015021341A2 (pt) | anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| BR112022004488A2 (pt) | Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos | |
| BR112017002440A2 (pt) | vírus da diarreia epizoótica porcina mutante para utilização em uma vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |